Effectiveness of diagnostic testing for Cervical Cancer and Human Papilloma Virus
DOI:
https://doi.org/10.19230/jonnpr.2953Keywords:
Cervical cáncer, human papilloma virus, screening, efficacyAbstract
Cervical cancer is one of the first 5 most common neoplasms in women in the world, derived from this over time that screening tests have emerged for its timely diagnosis (conventional cytology, liquid based cytology, visual inspection with acid acetic or Lugol, colposcopy ...); These tests have been perfected and even created. The detection reactions of causative agents (human papilloma virus) such as hybridization and PCR (polymerase chain reaction). As a result of this review, the use of screening tests such as conventional cytology, inspection with acetic acid or Lugol derived from its sensitivity and specificity that can lead to false positives in the diagnoses is negative or erroneous; This is true in cervical lesions or cervical cancer.
Downloads
References
Secretaria de Salud. Programa de Accion Especifico Prevencion y Control del Cancer de la Mujer 2013-2018. Programa. Mexico: Secretaria de Salud.
Olvera M. Prevalencia de cáncer cérvico uterino, lesiones premalignas y. Gaceta Hidalguense de Investigación en Salud. 2015; 8(2).
Herrera Y. Historia de la evolucion de las pruebas de tamizaje de cancer cervicouterino. Rev Med Inst Mex Seguro Soc. 2015; 53(6).
Gutierrez R. Utilidad de las tecnicas moleculares de deteccion de VPH en el control y prevecion del cancer cervicouterino. AMATGI. 2011; III(5).
Ramos G. Citologia cervical satisfactoria, extendido exocervical circular comparado con longitudinal. Rev Mex Inst Mex Seguro Soc. 2014; 52(6).
Carrascal M. Correlacion diagnostica de la citologia cervical versus colposcopia en lesiones premalignas de cancer cervicouterino. IPS Universitaria Barranquilla. 2013; 9(1).
Sanchez M. Certeza diagnostica de la colposcopia, citologia e histologia de las lesiones intraepiteliales del cervix. Rev Invest Med Sur Mex. 2013; 20(2).
Secretaria de Salud. Modificacion a la Norma Oficial Mexicana NOM- 014-SSA2-1994, para la prevencion, deteccion, diagnostico, tratamiento, control y vigilancia epidemiologica del cancer cervicouterino. Norma Oficial Mexicana. Mexico : Secretaria de Salud.
Contreras R. Papanicolaou y citologia liquida en diagnostico de cancer de cervix. Hospital civil de Maracay. Comunidad y Salud. 2015; 13(1).
Puerto de Amaya M. Citologia convencional y en base liquida en muestra compartida de tomas cervicouterinas. Repert Med Cir. 2015; 24(1).
Mittal S. Visual inspection with acetic as a screening test for cervical cancer. Biomed Res. 2013; 1(1).
R S. Análisis y registro de los resultados de la inspección visual con ácido acético al 5% (IVA). En R S. Manual practico para la deteccion visual de las neoplasias cervical. Lyon, Francia; 2005. p. 50.
Sankaranarayanan R. Early detection of cervical cancer with visual inspection methods: a summary of completed and on-going studies in India. Salud Publica Mex. 2003; 45(3).
Gonzalez G. Grado de efectividad y correlacion citologia-colposcopia utilizadas como pruebas diagnosticas en una entidad de salud de Santa Marta. DUAZARY. 2013; 10(2).
Ulrich K. 2017 update of the European Federation for Colposcopy (EFC) performance standards fot the practice of colposcopy. European Journal of Obstetrics & Gynecology and Reprouctive Biology. 2018; 224.
Nam K. Colposcopy at a turning point. Obstet Gynecol Sci. 2018; 61(1).
Zhao X. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10.669 Chinese women. Clinical Microbiology and Infection xxx. 2018.
Lactobellis M. Clinical validation of Realquality RQ-HPV screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening. Virology Journal. 2018; 15(48).
Gutierrez L. Molecular diagnosis of human papillomavirus in the development of cervical cancer. Salud publica de Mexico. 2009; 51.
Moller D. Clinical and analytical performance of the BD Onclarity HPV assay for detection of CIN2 lesiones on SurePath samples. Papillomavirus Research. ; 2.
Astudillo O. Diagnostico molecular del virus del papiloma humano. Panoram Medico. 2014; 8(1).
Sanoja L. Deteccion y tipificacion del virus del papiloma humano mediante reaccion en cadena de polimerasa, en muestras cervicales de estudiantes. Comunidad y Salud. 2013; 11(2).
Sharafadeen K. Prevalence and risk factors for genital hish-risk human papillomavirus infection among women attendin the outpatient clinics of a university teaching hospital in Lagos, Nigeria. Pan African Medical Journal. 2017; 28.
Beyazit F. The prevalence of human papillomavirus (HPV) genotypes detected by PCR in women tih normal and abnormal cervico-vaginal cytology. Comunidad y Salud. 2018; 11(2).
Aleksioska I. Prevalence of specific types of human papiloma virus in cervical intraepithelial lesions and cervical cancer in Macedonianan women. Med Arch. 2018; 71(1).
Downloads
Additional Files
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
